American Healthcare REIT (NYSE:AHR) Stock Gets Price Target Reduction from UBS Group

Key Points

• UBS Group lowered American Healthcare REIT’s price target from $63 to $62 while maintaining a “buy” rating, implying 18.12% upside from the stock’s $52.49 price.
• Analyst sentiment remains broadly positive: MarketBeat reports an average “Buy” rating and a $62 consensus target, with recent targets ranging from $60 to $68.
• American Healthcare REIT exceeded quarterly expectations, reporting $0.16 EPS versus $0.14 expected and $674.25 million in revenue, up 24.3% year over year; management’s FY 2026 EPS guidance is $2.15–$2.19.

American Healthcare REIT (NYSE:AHR - Get Free Report) had its target price decreased by equities research analysts at UBS Group from $63.00 to $62.00 in a report released on Tuesday, Benzinga reports. The brokerage currently has a "buy" rating on the stock. UBS Group's price target would suggest a potential upside of 18.12% from the company's current price.

AHR has been the topic of several other research reports. KeyCorp lifted their price target on shares of American Healthcare REIT from $58.00 to $68.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 19th. Barclays cut their price objective on American Healthcare REIT from $66.00 to $60.00 and set an "overweight" rating for the company in a research report on Tuesday. Truist Financial increased their price objective on American Healthcare REIT from $57.00 to $61.00 and gave the company a "buy" rating in a research report on Friday, August 14th. Royal Bank Of Canada raised their price objective on American Healthcare REIT from $56.00 to $61.00 and gave the stock an "outperform" rating in a research note on Friday, August 14th. Finally, Zacks Research upgraded American Healthcare REIT from a "hold" rating to a "strong-buy" rating in a report on Friday, October 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of "Buy" and an average target price of $62.00.

American Healthcare REIT Price Performance

NYSE AHR traded down $0.03 on Tuesday, reaching $52.49. The company's stock had a trading volume of 2,901,825 shares, compared to its average volume of 2,979,811. American Healthcare REIT has a twelve month low of $41.15 and a twelve month high of $58.70. The company has a debt-to-equity ratio of 0.24, a quick ratio of 0.48 and a current ratio of 0.48. The firm's 50 day moving average is $53.67 and its two-hundred day moving average is $51.74. The stock has a market cap of $11.44 billion, a PE ratio of 77.19, a PEG ratio of 1.24 and a beta of 0.79.

American Healthcare REIT (NYSE:AHR - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.02. American Healthcare REIT had a net margin of 4.84% and a return on equity of 3.63%. The company had revenue of $674.25 million for the quarter, compared to analysts' expectations of $645.30 million. During the same quarter in the previous year, the company posted $0.42 EPS. The business's revenue was up 24.3% compared to the same quarter last year. American Healthcare REIT has set its FY 2026 guidance at 2.150-2.190 EPS. As a group, sell-side analysts predict that American Healthcare REIT will post 2.18 EPS for the current year.

Insider Activity at American Healthcare REIT

In other news, EVP Mark Foster sold 2,000 shares of American Healthcare REIT stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $55.39, for a total value of $110,780.00. Following the transaction, the executive vice president directly owned 51,617 shares of the company's stock, valued at $2,859,065.63. This trade represents a 3.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.75% of the stock is currently owned by insiders.

Institutional Investors Weigh In On American Healthcare REIT

Several hedge funds have recently made changes to their positions in the company. Outlook Capital Management LLC bought a new stake in shares of American Healthcare REIT in the 2nd quarter valued at approximately $25,000. Manning & Napier Advisors LLC bought a new position in American Healthcare REIT during the first quarter valued at approximately $26,000. EverSource Wealth Advisors LLC raised its position in American Healthcare REIT by 193.2% during the first quarter. EverSource Wealth Advisors LLC now owns 1,032 shares of the company's stock valued at $49,000 after acquiring an additional 680 shares in the last quarter. Rockefeller Capital Management L.P. lifted its stake in American Healthcare REIT by 402.1% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,461 shares of the company's stock valued at $69,000 after acquiring an additional 1,170 shares during the last quarter. Finally, Independence Bank of Kentucky acquired a new stake in American Healthcare REIT in the second quarter valued at approximately $83,000. Hedge funds and other institutional investors own 16.68% of the company's stock.

About American Healthcare REIT

American Healthcare REIT, Inc NYSE: AHR is a real estate investment trust focused on owning and operating healthcare-related properties. The company seeks to provide real estate solutions for healthcare providers and operators while generating rental and operating income from a diversified portfolio.

Its portfolio includes outpatient medical properties, senior housing communities, skilled nursing facilities, hospitals and other healthcare assets. American Healthcare REIT also has exposure to healthcare operating businesses, including senior living and care services, through its relationship with Trilogy Health Services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.